Treatment with atogepant was safe, effective and well-tolerated over 12 weeks in those with episodic migraine who failed multiple conventional therapies, with significant reductions in mean monthly migraine days compared with placebo.
“Among people with episodic migraine, 27% experience more than 3 headache days per month,” Cristina Tassorelli, MD, a professor in the department of brain and behavioral science at the University of Pavia in Italy, and colleagues wrote The Lancet Neurology. “Scientific and expert consensus is generally that treating physicians should consider